BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Market Cap | $13.28B | $166.30M |
| Enterprise Value | $12.57B | $88.19M |
| PS Ratio | 18.63 | 3.65 |
Enterprise value
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| EV / Sales | 17.63 | 2.51 |
Income (trailing twelve months)
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Revenue | $713.07M | $58.34M |
| Gross Profit | $673.41M | $105.94M |
| Operating Income | -$497.80M | -$21.40M |
| EBITDA | -$492.72M | -$16.91M |
| EPS (Diluted) | -$3.57 | -$0.83 |
Margins
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Gross Margin | 94.4% | 52.9% |
| Operating Margin | -69.8% | -44.0% |
| EBITDA Margin | -69.1% | -30.2% |
| FCF Margin | -61.1% | -9.27% |
Returns
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -152.4% | -38.1% |
Growth
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 202.4% | 5.96% |
| Revenue Growth (3Y CAGR) | 86.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 127.4% | 6.48% |
Balance sheet
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $720.16M | $61.43M |
| Net Cash (Debt) | $720.16M | $15.35M |
| Net Cash Per Share | $3.68 | $0.66 |
| Equity (Book Value) | -$2.52B | $49.09M |
| Book Value Per Share | -$12.87 | $1.37 |
| Tangible Book Value | -$2.54B | $23.52M |
| Working Capital | $202.49M | $76.81M |
Financial position
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Current Ratio | 1.23 | 3.34 |
| Quick Ratio | 1.09 | 2.44 |
| Interest Coverage | -10.04 | -6.26 |
Cash flow (trailing twelve months)
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$434.37M | -$12.35M |
| Capital Expenditures | -$1.02M | -$1.08M |
| Free Cash Flow | -$435.39M | -$20.22M |
| FCF Per Share | -$2.23 | -$0.42 |
Efficiency
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.62 | 0.39 |
| Inventory Turnover | 1.12 | 2.70 |
| Revenue Per Employee | $855.00K | $404.87K |
| Employee Count | 834 | 74 |
Dividends and yields
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| FCF Yield | -3.28% | -8.72% |
| Buyback Yield | 1.58% | -0.59% |
| Shareholder Yield | 1.58% | 0.00% |
Shares
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 195,487,000 | 58,127,000 |
| Shares Change (YoY) | 2.29% | 10.9% |
| Shares Change (QoQ) | -0.22% | 0.54% |
| Float | 126,128,000 | 49,136,700 |
| Shares Held by Insiders | 35.5% | 11.6% |
| Shares Held by Institutions | 99.1% | 59.4% |
Scores
| Measure | BridgeBio Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -3.18 | -0.22 |
| Beneish M-Score | 8.38 | -2.62 |
Calculated by StockData from BridgeBio Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.